Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug3947 | multipeptide cocktail Wiki | 0.45 |
drug361 | BBV152B - Phase I Wiki | 0.45 |
drug158 | Ad5-nCoV Wiki | 0.45 |
Name (Synonyms) | Correlation | |
---|---|---|
drug1938 | MVC-COV1901 Wiki | 0.45 |
drug12 | 0.9% (w/v) saline Wiki | 0.45 |
drug363 | BBV152C - Phase I Wiki | 0.45 |
drug2812 | Recombinant novel coronavirus vaccine (Adenovirus type 5 vector) Wiki | 0.45 |
drug362 | BBV152B - Phase II Wiki | 0.45 |
drug2505 | Placebo - Phase I Wiki | 0.45 |
drug360 | BBV152A - Phase II Wiki | 0.45 |
drug3899 | intradermal injection of BCG Vaccine Wiki | 0.45 |
drug359 | BBV152A - Phase I Wiki | 0.45 |
drug80 | AG0301-COVID19 Wiki | 0.32 |
drug4004 | placebo Wiki | 0.26 |
drug128 | AZD1222 Wiki | 0.20 |
drug1366 | Gam-COVID-Vac Wiki | 0.17 |
drug2490 | Placebo Wiki | 0.12 |
Name (Synonyms) | Correlation | |
---|---|---|
D000257 | Adenoviridae Infections NIH | 0.40 |
D007239 | Infection NIH | 0.11 |
D018352 | Coronavirus Infections NIH | 0.07 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There are 5 clinical trials
Part I: 12 subjects will receive an open-label 500 µl subcutaneous injection via needle and syringe of the study IMP (CoVac-1). No more than one subject per day will be enrolled. 28 days following vaccination of the 12th volunteer, there will be an interim analysis of safety and a safety review by the data safety monitoring board (DSMB) as well as an amendment to the regulatory authorities (Paul-Ehrlich Institute and Ethics Committee) before proceeding to Part II. Part II: 12 subjects will receive an open-label 500 µl subcutaneous injection via needle and syringe of the study investigational medicinal product (IMP) (CoVac-1). 28 days following vaccination of the 12th volunteer, there will be an interim analysis of safety and a safety review by the DSMB whether to proceed to next Part III. Part III: 12 subjects will receive an open-label 500 µl subcutaneous injection via needle and syringe of the study IMP (CoVac-1). The aim of the clinical is to evaluate the safety and immunogenicity of a single use of a SARS-CoV-2-derived multi-peptide vaccine in combination with the toll like receptor (TLR)1/2 ligand XS15 in adults
Description: ECOG (Scale 0-5)
Measure: Safety- Eastern Cooperative Oncology Group (ECOG) Status Time: Day 28Description: temperature (in grade centigrade)
Measure: Safety -Vital Signs 2 Time: Day 28Description: blood pressure/pulse mmHg and bpm Follow-Up Days:Signs/symptoms, as assessed on volunteer's diary and visit
Measure: Safety -Vital Signs 3 Time: Day 28Description: Alkaline phosphatase (AP) Unit: U/l
Measure: Safety-Blood Chemistry and Coagulation 1 Time: Day 28Description: aspartate transaminase (AST/ SGOT) Unit: U/l
Measure: Safety-Blood Chemistry and Coagulation 2 Time: Day 28Description: hemoglobin (Hb) Differential cell counts should be performed at baseline, at each visit during vaccination phase and thereafter at investigators discretion. Clinical status and laboratory parameters are to be followed using individual institutional guidelines and the best clinical judgment of the responsible physician, which can involve more frequent testing Unit: g/dl
Measure: Safety-Hematology 1 Time: Day 28Description: red blood cells (RBC) Differential cell counts should be performed at baseline, at each visit during vaccination phase and thereafter at investigators discretion. Clinical status and laboratory parameters are to be followed using individual institutional guidelines and the best clinical judgment of the responsible physician, which can involve more frequent testing Unit: Mio/µl
Measure: Safety-Hematology 2 Time: Day 28Description: platelet count (PLT) Unit: 1000/µl Differential cell counts should be performed at baseline, at each visit during vaccination phase and thereafter at investigators discretion. Clinical status and laboratory parameters are to be followed using individual institutional guidelines and the best clinical judgment of the responsible physician, which can involve more frequent testing
Measure: Safety-Hematology 3 Time: Day 28Description: white blood cells (WBC) Unit: 1/µl Differential cell counts should be performed at baseline, at each visit during vaccination phase and thereafter at investigators discretion. Clinical status and laboratory parameters are to be followed using individual institutional guidelines and the best clinical judgment of the responsible physician, which can involve more frequent testing.
Measure: Safety-Hematology 4 Time: Day 28Description: 60 ml of heparin blood for immunomonitoring and analysis of peptide specific T-cell response will be analyzed by the Walz lab, KKE Translational Immunologie at the Department of Immunology, Tuebingen (central laboratory). Blood will be taken before peptide vaccination on V1, and during vaccination phase and follow-up at each visit. Unit:Counts
Measure: CoVac-1 specific T-cell response Time: Day 28This is a clinical trial to evaluate the safety and immunogenicity of a recombinant adenovirus 5 vectored COVID-19 vaccine (Ad5-nCoV) with two doses and with different adminstration routes in healthy adults aged 18 years and older.
Description: The occurrence of AE in all groups within 0-7 days after each vaccination;
Measure: Incidence of the AE in all groups Time: 0-7 days after each vaccinationDescription: Seroconversion rate the IgG antibody against SARS-CoV-2 measured on Day 28 after last vaccination
Measure: Seroconversion rate of the IgG antibody against SARS-CoV-2 Time: Day 28 after last vaccinationDescription: Geomean titers of the IgG antibody against SARS-CoV-2 measured on Day 28 after last vaccination
Measure: Geomean titers of the IgG antibody against SARS-CoV-2 Time: Day 28 after last vaccinationDescription: Seroconversion rate of the neutralizing antibody against SARS-CoV-2 measured on Day 28 after last vaccination
Measure: Seroconversion rate of the neutralizing antibody against SARS-CoV-2 Time: Day 28 after last vaccinationDescription: Geomean titers of the neutralizing antibody against SARS-CoV-2 measured on Day 28 after last vaccination
Measure: Geomean titers of the neutralizing antibody against SARS-CoV-2 Time: Day 28 after last vaccinationDescription: The occurrence of AE in all groups within 0-30 minutes and 0-28 days after each vaccination.
Measure: Incidence of the AE in all groups Time: 0-30 minutes, 0-28 days after each vaccinationDescription: The occurrence of Serious adverse events (SAE) in all groups within 6 months after the final vaccination.
Measure: Incidence of Serious adverse events (SAE) in all groups Time: 6 months after the final vaccinationDescription: Geomean titers of the IgG antibody against SARS-CoV-2 measured on Day 0, 14, 28 and 56 after first vaccination and on Day 14 and Day168 after last vaccination.
Measure: Geomean titers of the IgG antibody against SARS-CoV-2 Time: Day 0, 14, 28 and 56 after first vaccination and Day 14 and Day168 after last vaccination.Description: Seroconversion rate of the IgG antibody against SARS-CoV-2 measured on Day 0, 14, 28 and 56 after first vaccination and on Day 14 and Day168 after last vaccination.
Measure: Seroconversion rate of the IgG antibody against SARS-CoV-2 Time: Day 0, 14, 28 and 56 after first vaccination and Day 14 and Day168 after last vaccination.Description: Geomean titers of the neutralizing antibody against SARS-CoV-2 measured on Day 0, 14, 28 and 56 after first vaccination and on Day 14 and Day168 after last vaccination.
Measure: Geomean titers of the neutralizing antibody against SARS-CoV-2 Time: Day 0, 14, 28 and 56 after first vaccination and Day 14 and Day168 after last vaccination.Description: Seroconversion rate of the neutralizing antibody against SARS-CoV-2 measured on Day 0, Day14, Day 28 or Day 56 after first vaccination and on day 14, day 28 and day168 after last vaccination.
Measure: Seroconversion rate of the neutralizing antibody against SARS-CoV-2 Time: Day 0, 14, 28 and 56 after first vaccination and on Day 14 and Day168 after last vaccination.Description: The positive rate of IFN-γ stimulated by S protein overlapping peptide library detected by ELISpot on Day 0 and Day 14 after each vaccination
Measure: Cellular immune response by ELISpot Time: Day 0 and Day 14 after each vaccinationDescription: Geomean titers of neutralizing antibody response to Ad5-vector on Day 0, 14 and 28 after each vaccination.
Measure: Geomean titers of neutralizing antibody response to Ad5-vector Time: Day 0, 14 and 28 after each vaccination.Description: The positive rate of the specific cytokines expressed by CD4+ and CD8+ T lymphocytes stimulated by S protein overlapping peptide library detected by intracellular cytokine staining on Day 0 and Day 14 after each vaccination
Measure: Cellular immune response by ICS Time: Day 0 and Day 14 after each vaccinationDescription: Geomean titers of the IgA antibody against SARS-CoV-2 on Day 0, 14 and 28 after each vaccination.
Measure: Geomean titers of the IgA antibody against SARS-CoV-2 Time: Day 0, 14 and 28 after each vaccinationThis is a phase II, randomised, double-blinded and placebo-controlled clinical trial in healthy adults above 18 years of age. This clinical trial is designed to evaluate the immunogenicity and safety of Ad5-nCoV which encodes for a full-length spike (S) protein of SARS-CoV-2.
This is a phase I prospective, open-labeled, single-center study to evaluate the safety and immunogenicity of MVC-COV1901.
Description: Incidence of solicited adverse events (AEs) after vaccination, Incidence of unsolicited AEs and other AEs after vaccination, Incidence of laboratory abnormality after vaccination, Incidence of adverse event of special interest (AESI) and serious adverse events (SAEs) after vaccination
Measure: Safety of MVC-COV1901 Time: Day 1 to 28 days after second vaccinationDescription: Geometric mean titer (GMT), Seroconversion rate (SCR), and GMT ratio
Measure: Immunogenicity (neutralizing antibody titers and antigen specific binding antibody titers) Time: 14 days, 28 days after each vaccination, and 180 days after second vaccination.Description: The positive rate of cellular mediated immune response
Measure: Immunogenicity (antigen specific cellular immune responses) Time: 28 days and 180 days after second vaccinationDescription: Incidence of other adverse events, Incidence of adverse event of special interest (AESI) and serious adverse events (SAEs) within the study period
Measure: Safety of MVC-COV1901 Time: Day 1 to Day 209Double blind, Multi-Centre study to evaluate the safety, reactogenicity, tolerability, and immunogenicity of three investigational vaccine groups and one placebo group in healthy volunteers who receive two intramuscular doses of BBV152 vaccine formulations and placebo. A total sample size of 755 healthy volunteers, with 375 and 380 volunteers in phase 1 and 2 studies, respectively.
Description: Safety
Measure: Phase 1: Occurrence of adverse events and Serious Adverse events Time: Through study completion, an average of 6 monthsDescription: Pre- and Post-vaccination immune response
Measure: Phase 2: Evaluation of Neutralizing Antibody Titers Time: Through study completion, an average of 6 monthsDescription: Pre- and Post-vaccination immune response
Measure: Phase 1: Evaluation of Neutralizing Antibody Titers Time: Through study completion, an average of 6 monthsDescription: Safety
Measure: Phase 2: Occurrence of adverse events and Serious Adverse events Time: Through study completion, an average of 6 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports